Low-dose Interleukin-2 in Women With Unexplained Miscarriages (FaCIL-2)
Regulatory T-cell Induction by Low-dose Interleukin-2 in Women With Unexplained Repeated Spontaneous Early Miscarriages
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
About 1 to 3% of women of childbearing age have repeated early spontaneous miscarriages that may be related to parental chromosomal abnormalities, uterine abnormalities, hormonal causes, infectious etiology, thrombophilia ... When one of these known causes is excluded, it is unexplained miscarriages of which half would be due to an immunological deregulation of the mother causing a decrease of the tolerance to the fetus.
In this context, the stimulation of regulatory T cells (Tregs) by low dose IL-2 is a therapeutic option with a rational, preclinical and clinical data very favorable.
In humans, low dose IL-2 allows preferential activation of Tregs and is very well tolerated. Several therapeutic trials have shown its efficiencies.
These elements make it possible to envisage the development of a therapeutic to prevent fetal rejection by IL2-fd on the women with spontaneous miscarriages by an immunological deregulation.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: David Klatzmann, Pr
- Phone Number: +331 42 16 74 61
- Email: david.klatzmann@upmc.fr
Study Contact Backup
- Name: Arsène Mékinian, Dr
- Phone Number: +33 1 48 02 63 96
- Email: arsene.mekinian@aphp.fr
Study Locations
-
-
Hopital Saint Antoine
-
Paris, Hopital Saint Antoine, France, 75012
- Mekinian
-
-
Hopital Tenon
-
Paris, Hopital Tenon, France, 75020
- Bornes
-
-
Hopital Trousseau
-
Paris, Hopital Trousseau, France, 75012
- Kayem
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Woman with at least 5 consecutive early miscarriages less than 14 weeks of amenorrhea and unexplained after the usual check-up;
- Volunteer to participate in the trial and having given written consent after appropriate information.
Exclusion Criteria:
- Uterine or pelvic abnormality: uterine malformation, intracavitary fibroid, synechiae, polyp, hydrosalpinx;
- Balanced translocations in both spouses;
- Diabetes type I or II;
- Sickle cell disease;
- Contraindication to pregnancy;
- Constitutional or acquired thrombophilia (protein deficit C, S, ATIII, homozygous factor V or II deficiency, antiphospholipid syndrome, antithyroid antibodies positive, celiac disease, hyperhomocysteinemia);
- Ovarian insufficiency (AMH <1 ng/ml); AFC < 4
- Significant spermogram abnormalities and DNA fragmented more than 30%
- Active HIV or HCV infection;
- Main known contraindications to treatment with IL-2:
- Hypersensitivity to the active substance or to any of the excipients;
- Signs of progressive infection requiring antibiotic therapy;
- History of organ allograft;
- Pre-existing autoimmune disease;
- Leukocytes <4000 / mm3; platelets <100,000 / mm3; hematocrit <30%;
- hepatic or renal insufficiency;
- depression;
- significant history or existence of a serious heart disease (in doubtful cases, perform a stress test);
- patients with autoimmune disease;
- patients with an infection (septicemia, bacterial endocarditis, septic thrombophlebitis, peritonitis and pneumonia);
- pregnancy;
- Treatment with immunomodulators, immunosuppressants (class L04A of the ATC classification), in particular systemic corticosteroids, as well as aspirin and low molecular weight heparin;
- No affiliation to a social security;
- Person who has already been included in this study or in another at the same time;
- Major incapacitated patient (tutorship / curatorship);
- Patient with an allergy to taking IL2-fd;
- Participants who would present professional risk factors (eg ionizing exposure);
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
Low-dose IL-2
|
Subcutaneous injection of low dose of IL-2 for induction course of 5 days, the 10th day after the beginning of periods.
At most 5 courses of low dose of IL-2.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
Time Frame: At the day 38 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1]
|
Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2
|
At the day 38 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1]
|
|
Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
Time Frame: At the day 66 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2
|
At the day 66 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
|
Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
Time Frame: At the day 94 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2
|
At the day 94 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
|
Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
Time Frame: At the day 122 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2
|
At the day 122 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
|
Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)
Time Frame: At the day 150 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 11
|
Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2
|
At the day 150 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 11
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)
Time Frame: At the day 38 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2
|
At the day 38 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
|
Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)
Time Frame: At the day 66 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2
|
At the day 66 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
|
Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)
Time Frame: At the day 94 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2
|
At the day 94 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
|
Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)
Time Frame: At the day 122 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2
|
At the day 122 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
|
|
Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)
Time Frame: At the day 150 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 11
|
Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2
|
At the day 150 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 11
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: David Klatzmann, Pr, Pitié Salpètrière APHP Paris
- Study Director: Arsene Mékinian, Dr, Saint Antoine APHP Paris
- Study Director: Gilles Kayem, Pr, Trousseau APHP Paris
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Pregnancy Complications
- Abortion, Spontaneous
- Abortion, Habitual
- Peptides
- Amino Acids, Peptides, and Proteins
- Proteins
- Biological Factors
- Intercellular Signaling Peptides and Proteins
- Cytokines
- Interleukins
- Lymphokines
- Interleukin-2
Other Study ID Numbers
Other Study ID Numbers
- APHP180256
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.